FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3085103914> ?p ?o ?g. }

• W3085103914 endingPage "488" @default.
• W3085103914 startingPage "475" @default.
• W3085103914 abstract "Abstract Background Doxorubicin (DOXO) chemotherapy increases risk for cardiovascular disease in part by inducing endothelial dysfunction in conduit arteries. However, the mechanisms mediating DOXO-associated endothelial dysfunction in (intact) arteries and treatment strategies are not established. Objectives We tested the hypothesis that DOXO impairs endothelial function in conduit arteries via excessive mitochondrial reactive oxygen species (ROS) and that these effects could be prevented by treatment with a mitochondrial-targeted antioxidant (MitoQ). Methods Endothelial function (endothelium-dependent dilation [EDD] to acetylcholine) and vascular mitochondrial ROS were assessed 4 weeks following administration (10 mg/kg intraperitoneal injection) of DOXO. A separate cohort of mice received chronic (4 weeks) oral supplementation with MitoQ (drinking water) for 4 weeks following DOXO. Results EDD in isolated pressurized carotid arteries was 55% lower 4 weeks following DOXO (peak EDD, DOXO: 42 ± 7% vs. sham: 94 ± 3%; p = 0.006). Vascular mitochondrial ROS was 52% higher and manganese (mitochondrial) superoxide dismutase was 70% lower after DOXO versus sham (p = 0.0008). Endothelial function was rescued by administration of the mitochondrial-targeted antioxidant, MitoQ, to the perfusate. Exposure to plasma from DOXO-treated mice increased mitochondrial ROS in cultured endothelial cells. Analyses of plasma showed differences in oxidative stress-related metabolites and a marked reduction in vascular endothelial growth factor A in DOXO mice, and restoring vascular endothelial growth factor A to sham levels normalized mitochondrial ROS in endothelial cells incubated with plasma from DOXO mice. Oral MitoQ supplementation following DOXO prevented the reduction in EDD (97 ± 1%; p = 0.002 vs. DOXO alone) by ameliorating mitochondrial ROS suppression of EDD. Conclusions DOXO-induced endothelial dysfunction in conduit arteries is mediated by excessive mitochondrial ROS and ameliorated by mitochondrial-specific antioxidant treatment. Mitochondrial ROS is a viable therapeutic target for mitigating arterial dysfunction with DOXO." @default.
• W3085103914 created "2020-09-21" @default.
• W3085103914 creator A5001348940 @default.
• W3085103914 creator A5015893927 @default.
• W3085103914 creator A5029081520 @default.
• W3085103914 creator A5045175167 @default.
• W3085103914 creator A5048393954 @default.
• W3085103914 creator A5053802979 @default.
• W3085103914 creator A5077010538 @default.
• W3085103914 creator A5091792035 @default.
• W3085103914 date "2020-09-01" @default.
• W3085103914 modified "2023-10-12" @default.
• W3085103914 title "Doxorubicin-Induced Oxidative Stress and Endothelial Dysfunction in Conduit Arteries Is Prevented by Mitochondrial-Specific Antioxidant Treatment" @default.
• W3085103914 cites W1492360552 @default.
• W3085103914 cites W1492660023 @default.
• W3085103914 cites W1585518597 @default.
• W3085103914 cites W1623473717 @default.
• W3085103914 cites W1920198420 @default.
• W3085103914 cites W19371791 @default.
• W3085103914 cites W1965295365 @default.
• W3085103914 cites W1969347062 @default.
• W3085103914 cites W1973590495 @default.
• W3085103914 cites W1980458129 @default.
• W3085103914 cites W1981926426 @default.
• W3085103914 cites W1984415019 @default.
• W3085103914 cites W1988079533 @default.
• W3085103914 cites W1991008912 @default.
• W3085103914 cites W1997611244 @default.
• W3085103914 cites W2010183849 @default.
• W3085103914 cites W2011344898 @default.
• W3085103914 cites W2015376899 @default.
• W3085103914 cites W2020080089 @default.
• W3085103914 cites W2020585998 @default.
• W3085103914 cites W2021295284 @default.
• W3085103914 cites W2029587579 @default.
• W3085103914 cites W2038852529 @default.
• W3085103914 cites W2042510310 @default.
• W3085103914 cites W2046086299 @default.
• W3085103914 cites W2060697601 @default.
• W3085103914 cites W2079442927 @default.
• W3085103914 cites W2098475099 @default.
• W3085103914 cites W2106111900 @default.
• W3085103914 cites W2107914421 @default.
• W3085103914 cites W2134682606 @default.
• W3085103914 cites W2137057701 @default.
• W3085103914 cites W2137114865 @default.
• W3085103914 cites W2139020323 @default.
• W3085103914 cites W2160375807 @default.
• W3085103914 cites W2162509257 @default.
• W3085103914 cites W2171190458 @default.
• W3085103914 cites W2218389985 @default.
• W3085103914 cites W2267822864 @default.
• W3085103914 cites W2540430101 @default.
• W3085103914 cites W2561396377 @default.
• W3085103914 cites W2586749137 @default.
• W3085103914 cites W2735543690 @default.
• W3085103914 cites W2773236325 @default.
• W3085103914 cites W2791893068 @default.
• W3085103914 cites W2796629168 @default.
• W3085103914 cites W2801870670 @default.
• W3085103914 cites W2914172646 @default.
• W3085103914 cites W2915535443 @default.
• W3085103914 cites W2954275614 @default.
• W3085103914 cites W2991872590 @default.
• W3085103914 doi "https://doi.org/10.1016/j.jaccao.2020.06.010" @default.
• W3085103914 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7561020" @default.
• W3085103914 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33073250" @default.
• W3085103914 hasPublicationYear "2020" @default.
• W3085103914 type Work @default.
• W3085103914 sameAs 3085103914 @default.
• W3085103914 citedByCount "27" @default.
• W3085103914 countsByYear W30851039142021 @default.
• W3085103914 countsByYear W30851039142022 @default.
• W3085103914 countsByYear W30851039142023 @default.
• W3085103914 crossrefType "journal-article" @default.
• W3085103914 hasAuthorship W3085103914A5001348940 @default.
• W3085103914 hasAuthorship W3085103914A5015893927 @default.
• W3085103914 hasAuthorship W3085103914A5029081520 @default.
• W3085103914 hasAuthorship W3085103914A5045175167 @default.
• W3085103914 hasAuthorship W3085103914A5048393954 @default.
• W3085103914 hasAuthorship W3085103914A5053802979 @default.
• W3085103914 hasAuthorship W3085103914A5077010538 @default.
• W3085103914 hasAuthorship W3085103914A5091792035 @default.
• W3085103914 hasBestOaLocation W30851039141 @default.
• W3085103914 hasConcept C126322002 @default.
• W3085103914 hasConcept C127413603 @default.
• W3085103914 hasConcept C164705383 @default.
• W3085103914 hasConcept C185592680 @default.
• W3085103914 hasConcept C2776151105 @default.
• W3085103914 hasConcept C2776694085 @default.
• W3085103914 hasConcept C2778004101 @default.
• W3085103914 hasConcept C2780972559 @default.
• W3085103914 hasConcept C2781303535 @default.
• W3085103914 hasConcept C28859421 @default.
• W3085103914 hasConcept C48349386 @default.
• W3085103914 hasConcept C55493867 @default.
• W3085103914 hasConcept C71924100 @default.
• W3085103914 hasConcept C78519656 @default.

• next